Dilemma of denosumab therapy: rebound fractures with denosumab cessation or dose delay.

Intern Med J

Department of Endocrinology, Monash Health, Melbourne, Victoria, Australia.

Published: February 2021

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.15189DOI Listing

Publication Analysis

Top Keywords

dilemma denosumab
4
denosumab therapy
4
therapy rebound
4
rebound fractures
4
fractures denosumab
4
denosumab cessation
4
cessation dose
4
dose delay
4
dilemma
1
therapy
1

Similar Publications

Bone Health ECHO (Extension for Community Healthcare Outcomes) is a virtual community of practice, where healthcare professionals have met via videoconferencing weekly since 2015. This model of learning is focused on short didactics and the presentation of real but de-identified patient cases followed by highly interactive discussions. These are often clinical situations with diagnostic and therapeutic dilemmas that are not readily addressed by randomized placebo-controlled clinical trials and clinical practice guidelines.

View Article and Find Full Text PDF

Background: There can be a diagnostic challenge in differentiating giant cell tumor of bone (GCTB) from its mimics. Lately, histone H 3 F 3 A (Histone 3.3 ) G34W has been identified as a promising immunohistochemical marker.

View Article and Find Full Text PDF

Oral squamous cell carcinoma (OSCC) may arise in the the alveolar ridge (in a minority of cases). Smoking, chronic mucosal injuries, and poor oral hygiene are involved in its pathogenesis. It mostly occurs to men instead of women and affects the mandible on a 3:2 ratio to the maxilla.

View Article and Find Full Text PDF

Giant cell tumor (GCT) is a primary bone tumor of long bones, which can rarely involve the vertebrae. Contiguous vertebral involvement by GCT is a rare presentation and poses a diagnostic dilemma on imaging. We report a case of GCT involving three contiguous lumbar vertebrae causing vertebral collapse along with a large soft tissue component.

View Article and Find Full Text PDF

Treatment Challenges When Stopping Denosumab.

Ir Med J

March 2022

Bone Health and Osteoporosis Unit, Mercer's Institute for Successful Ageing, St. James's Hospital.

Introduction Denosumab is commonly used to treat osteoporosis. However, discontinuation results in rebound bone loss and increased vertebral fracture risk. We report a clinical case series, illustrating the dilemma in deciding the best treatment should denosumab be stopped.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!